Alector, Inc. Common Stock
ALECAlector, Inc. (ALEC) is a biotechnology company focused on discovering and developing immuno-neurology medicines to treat neurodegenerative diseases and cancer. The company's platform leverages insights into the immune system's role in neurodegeneration, aiming to develop targeted therapies for conditions such as Alzheimer’s disease, ALS, and other neuroinflammatory disorders.
Company News
The dementia therapeutics market is experiencing significant growth driven by emerging disease-modifying treatments for early-stage Alzheimer's and promising therapies for other dementia subtypes. With approximately 55 million people globally affected by dementia, the market is shifting toward proactive intervention with drugs like LEQEMBI and KI...
Alector's Phase 3 clinical trial for latozinemab in frontotemporal dementia failed to meet primary endpoints, causing a 50% stock price drop and triggering a potential shareholder lawsuit.
Biotechnology company Alector announced that its drug latozinemab did not meet safety and efficacy criteria in a Phase 3 clinical trial for treating frontotemporal dementia (FTD) caused by GRN gene variants. Despite increasing progranulin protein levels, the drug did not slow disease progression.
Alector, a late-stage clinical biotechnology company, announced that it will participate in upcoming investor conferences, where it will present its therapies for neurodegenerative diseases.
Alector, a late-stage clinical biotechnology company, provided an update on its pipeline, including the anticipated topline data from the pivotal INFRONT-3 Phase 3 trial of latozinemab in frontotemporal dementia with a granulin gene mutation, and the ongoing PROGRESS-AD Phase 2 trial of AL101/GSK4527226 for early Alzheimer's disease. The company ...
